Unfortunately, many of the adjuvant Trastuzumab trials excluded HER2+ T1aN0 or T1bN0 cancers because of the perceived low risk of recurrence and there remains a lack of robust evidence which can be used to estimate the balance of benefits and risks of biological therapy in these patients (Banerjee and Smith, 2010). This evidence concerns the gene ERBB2 and cancer.